{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=LCC&page=43",
    "query": {
      "condition": "LCC",
      "page": 43
    },
    "page_size": 10
  },
  "pagination": {
    "page": 43,
    "page_size": 10,
    "total_count": 1039,
    "total_pages": 104,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=LCC&page=44&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=LCC&page=42&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T22:22:51.410Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06358001",
      "title": "EchoTip AcuCore Post-Market Clinical Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Adenocarcinoma",
        "Neuroendocrine Tumors",
        "Hepatocellular Carcinoma",
        "Cholangiocarcinoma",
        "Malignant Lymphoma",
        "Metastasis",
        "Chronic Pancreatitis",
        "Autoimmune Pancreatitis"
      ],
      "interventions": [
        {
          "name": "EchoTip AcuCore",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Cook Research Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 183,
      "start_date": "2024-08-05",
      "completion_date": "2025-07-19",
      "has_results": false,
      "last_update_posted_date": "2025-09-22",
      "last_synced_at": "2026-10-29T22:22:51.410Z",
      "location_count": 8,
      "location_summary": "Orange, California • Denver, Colorado • Gainesville, Florida + 4 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06358001"
    },
    {
      "nct_id": "NCT06198296",
      "title": "Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatoblastoma",
        "Hepatocellular Carcinoma",
        "Wilms Tumor",
        "Malignant Rhabdoid Tumor",
        "Yolk Sac Tumor",
        "Rhabdomyosarcoma",
        "Liposarcoma",
        "Embryonal Sarcoma of Liver"
      ],
      "interventions": [
        {
          "name": "21.15.GPC3-CAR T cells",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 21,
      "start_date": "2025-06-10",
      "completion_date": "2043-02-01",
      "has_results": false,
      "last_update_posted_date": "2025-11-03",
      "last_synced_at": "2026-10-29T22:22:51.410Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06198296"
    },
    {
      "nct_id": "NCT03303469",
      "title": "Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) Imaging",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "FMISO",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2017-10-30",
      "completion_date": "2021-01-06",
      "has_results": true,
      "last_update_posted_date": "2021-02-21",
      "last_synced_at": "2026-10-29T22:22:51.410Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03303469"
    },
    {
      "nct_id": "NCT01911273",
      "title": "A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Hepatocellular"
      ],
      "interventions": [
        {
          "name": "PF-03446962",
          "type": "DRUG"
        },
        {
          "name": "Best Supportive Care",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2013-10",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2015-10-28",
      "last_synced_at": "2026-10-29T22:22:51.410Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01911273"
    },
    {
      "nct_id": "NCT07227012",
      "title": "Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Hepatocellular",
        "Hepatocellular Cancer",
        "Hepatocellular Carcinoma",
        "Unresectable Hepatocellular Carcinoma",
        "Liver Neoplasms",
        "Advanced Hepatocellular Carcinoma",
        "Metastatic Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "PF-08634404",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 138,
      "start_date": "2025-12-01",
      "completion_date": "2028-10-17",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-10-29T22:22:51.410Z",
      "location_count": 46,
      "location_summary": "Irvine, California • Los Angeles, California • Orange, California + 21 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07227012"
    },
    {
      "nct_id": "NCT00081900",
      "title": "A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible for Surgical Care",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Hepatocellular"
      ],
      "interventions": [
        {
          "name": "DENSPM )",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2004-03",
      "completion_date": "2007-11",
      "has_results": false,
      "last_update_posted_date": "2015-04-13",
      "last_synced_at": "2026-10-29T22:22:51.410Z",
      "location_count": 8,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts • Nashville, Tennessee + 3 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00081900"
    },
    {
      "nct_id": "NCT02191878",
      "title": "Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma",
        "Hepatoma",
        "Liver Cancer, Adult",
        "Liver Cell Carcinoma, Adult"
      ],
      "interventions": [
        {
          "name": "TKM-080301",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arbutus Biopharma Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2014-06",
      "completion_date": "2016-07",
      "has_results": false,
      "last_update_posted_date": "2019-01-16",
      "last_synced_at": "2026-10-29T22:22:51.410Z",
      "location_count": 5,
      "location_summary": "Tucson, Arizona • San Francisco, California • Kansas City, Missouri + 2 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02191878"
    },
    {
      "nct_id": "NCT01076517",
      "title": "A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Liver Cancer"
      ],
      "interventions": [
        {
          "name": "Therasphere",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2021-04-01",
      "last_synced_at": "2026-10-29T22:22:51.410Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01076517"
    },
    {
      "nct_id": "NCT02699190",
      "title": "LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Leukodystrophy",
        "White Matter Disease",
        "4H Syndrome",
        "Adrenoleukodystrophy",
        "AMN",
        "ALD",
        "ALD (Adrenoleukodystrophy)",
        "X-linked Adrenoleukodystrophy",
        "X-ALD",
        "Adrenomyeloneuropathy",
        "Aicardi Goutieres Syndrome",
        "AGS",
        "Alexander Disease",
        "Alexanders Leukodystrophy",
        "AxD",
        "ADLD",
        "Canavan Disease",
        "CTX",
        "Cerebrotendinous Xanthomatoses",
        "Krabbe Disease",
        "GALC Deficiency",
        "Globoid Leukodystrophy",
        "TUBB4A-Related Leukodystrophy",
        "H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum",
        "HBSL",
        "HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity",
        "LBSL",
        "Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder)",
        "Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation",
        "ALSP",
        "CSF1R Gene Mutation",
        "HCC - Hypomyelination and Congenital Cataract",
        "MLC1",
        "Megalencephalic Leukoencephalopathy With Subcortical Cysts 1",
        "MLD",
        "Metachromatic Leukodystrophy",
        "PMD",
        "Pelizaeus-Merzbacher Disease",
        "PLP1 Null Syndrome",
        "PLP1 Gene Duplication | Blood or Tissue | Mutations",
        "Pelizaeus-Merzbacher-Like Disease, 1",
        "Peroxisomal Biogenesis Disorder",
        "Zellweger Syndrome",
        "Refsum Disease",
        "Salla Disease",
        "Sialic Storage Disease",
        "Sjögren",
        "Sjogren-Larsson Syndrome",
        "Van Der Knapp Disease",
        "Vanishing White Matter Disease",
        "Charcot-Marie-Tooth",
        "CMT",
        "Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency",
        "Allan-Herndon-Dudley Syndrome",
        "Cadasil",
        "Cockayne Syndrome",
        "Multiple Sulfatase Deficiency",
        "Gangliosidoses",
        "GM2 Gangliosidosis",
        "BPAN",
        "Labrune Syndrome",
        "LCC",
        "Mucopolysaccharidoses",
        "TBCK-Related Intellectual Disability Syndrome"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "Up to 18 Years"
      },
      "enrollment_count": 236,
      "start_date": "2017-01-06",
      "completion_date": "2024-10-31",
      "has_results": true,
      "last_update_posted_date": "2025-11-10",
      "last_synced_at": "2026-10-29T22:22:51.410Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02699190"
    },
    {
      "nct_id": "NCT00054262",
      "title": "T900607 in Treating Patients With Unresectable Liver Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Liver Cancer"
      ],
      "interventions": [
        {
          "name": "T900607",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University Hospitals Seidman Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2002-11",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2013-07-18",
      "last_synced_at": "2026-10-29T22:22:51.410Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00054262"
    }
  ]
}